<DOC>
	<DOCNO>NCT02978118</DOCNO>
	<brief_summary>This pilot study purpose study describe peripheral circulate immune cell profile baseline change treatment immune checkpoint inhibitor renal cell carcinoma urothelial carcinoma .</brief_summary>
	<brief_title>Exploring Relevant Immune-based Biomarkers Circulating Tumor Cells During Treatment With Immune Checkpoint Inhibitors Genitourinary Malignancies ( CTC Immune Based Biomarkers )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Group A : Patients eligible inclusion study ALL follow criterion apply : 1 . Histologically confirm diagnosis renal cell carcinoma . Clear cell nonclear cell carcinoma ( papillary , chromophobe , collect duct , medullary ) allow . 2 . Evidence metastatic disease site recent imaging scan 3 . Planned initiation treatment immune modulatory agent target follow : PD1 , PDL1 , CTLA4 , CD27 , OX40 , LAG3 4 . Age &gt; 18 year . 5 . Ability understand willingness sign write informed consent document . Group B : Patients eligible inclusion study ALL follow criterion apply : 1 . Histologically confirm diagnosis urothelial carcinoma . Nontransitional cell carcinoma ( adenocarcinoma squamous cell carcinoma ) allow . 2 . Evidence metastatic disease site recent imaging scan 3 . Planned initiation treatment immune modulatory agent target follow : PD1 , PDL1 , CTLA4 , CD27 , OX40 , LAG3 4 . Age &gt; 18 year . 5 . Ability understand willingness sign write informed consent document . A patient eligible inclusion study follow criterion apply : 1 . History intercurrent past medical psychiatric illness would make participation blood draw protocol difficult feasible discretion principal investigator coinvestigator ( ) . 2 . Treatment systemic steroid dose formulation ( include hydrocortisone , prednisone , methylprednisolone ( Solumedrol ) , dexamethasone ) , within 4 week consent plan initiation steroid consent ( unplanned steroid initiation treatment immune related adverse event allow ) . Chronic treatment steroid physiological replacement adrenal insufficiency allow . 3 . Treatment immunosuppressive agent ( include mycophenolate mofetil ( Cellcept ) , mycophenolate sodium ( Myfortic ) , rituximab ( Rituxan ) , tacrolimus ( Prograf ) , sirolimus ( Rapamune ) , cyclosporine ( Sandimmune ) , TNFa inhibitor infliximab , etanercept adalimumab , methotrexate , azathioprine , dactinomycin ) within 4 week consent plan initiation agent 12 week consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>